The oral poly(ADP-ribose) polymerase (PARP) inhibitor olaparib ( Lynparza – AstraZeneca) has now been approved by the FDA for use in combination with abiraterone ( Zytiga , and others) and either prednisone…
Med Lett Drugs Ther. 2023 Jun 26; 65(1679):e106-7 doi:10.58347/tml.2023.1679g
The oral poly(ADP-ribose) polymerase (PARP) inhibitor olaparib ( Lynparza – AstraZeneca) has now been approved by the FDA for use in combination with abiraterone ( Zytiga , and others) and either prednisone or prednisolone for treatment of adults with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Olaparib was previously approved by the FDA for treatment of adults with deleterious or suspected deleterious germline or somatic homologous recombinant repair (HRR) genemutated mCRPC who progressed on prior treatment with enzalutamide (Xtandi) or abiraterone.
The oral poly(ADP-ribose) polymerase (PARP) inhibitor olaparib ( Lynparza – AstraZeneca) has been approved by the FDA for adjuvant treatment of adults with deleterious or suspected deleterious germline…
Med Lett Drugs Ther. 2023 Apr 17; 65(1674):e77-8 doi:10.58347/tml.2023.1674j
The oral poly(ADP-ribose) polymerase (PARP) inhibitor olaparib ( Lynparza – AstraZeneca) has been approved by the FDA for adjuvant treatment of adults with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative, high-risk early breast cancer who received prior neoadjuvant or adjuvant chemotherapy. The drug was previously approved for treatment of adults with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer who received chemotherapy in the neoadjuvant, adjuvant, or metastatic setting.
The FDA has approved sacituzumab govitecan-hziy ( Trodelvy – Immunomedics), a trophoblast cell-surface antigen-2 (Trop-2)-directed antibody and topoisomerase inhibitor conjugate, for treatment of adults with…
Med Lett Drugs Ther. 2021 Feb 8; 63(1617):e24-5
The FDA has approved sacituzumab govitecan-hziy ( Trodelvy – Immunomedics), a trophoblast cell-surface antigen-2 (Trop-2)-directed antibody and topoisomerase inhibitor conjugate, for treatment of adults with metastatic triple-negative breast cancer who have received ≥2 prior therapies for metastatic disease. It is the first Trop-2-directed antibody-drug conjugate to become available in the US.
Three oral poly(ADP-ribose) polymerase (PARP) inhibitors have been approved by the FDA for treatment of advanced, recurrent ovarian cancer. Olaparib ( Lynparza – AstraZeneca), niraparib ( Zejula – Tesaro),…
Med Lett Drugs Ther. 2017 Dec 4; 59(1535):200-2
Three oral poly(ADP-ribose) polymerase (PARP) inhibitors have been approved by the FDA for treatment of advanced, recurrent ovarian cancer. Olaparib ( Lynparza – AstraZeneca), niraparib ( Zejula – Tesaro), and rucaparib ( Rubraca – Clovis) are each approved for somewhat different indications and for patients with different biomarkers (see Table 2).
The FDA has approved the oral poly (ADP-ribose) polymerase (PARP) inhibitor olaparib ( Lynparza – Astra-Zeneca) as monotherapy for treatment of women with advanced ovarian cancer who have BRCA1/2 germline…
Med Lett Drugs Ther. 2016 Feb 29; 58(1489):e32-3
The FDA has approved the oral poly (ADP-ribose) polymerase (PARP) inhibitor olaparib ( Lynparza – Astra-Zeneca) as monotherapy for treatment of women with advanced ovarian cancer who have BRCA1/2 germline mutations and have received at least 3 prior lines of chemotherapy. Olaparib is the first PARP inhibitor to be approved in the US. It is approved outside the US for maintenance treatment of relapsed BRCA-mutated ovarian cancer.